
"Of course, this would be in violation of some rules of time travel – right, Biff?" Knowing Nothing Has Meant Everything ashpublications.org/ashclini…

Medical Director @caseccc CRO | Associ Prof | Cleveland Clinic Taussig Cancer Institute | EIC @ASHClinicalNews | Opinions here are mine

"Of course, this would be in violation of some rules of time travel – right, Biff?" Knowing Nothing Has Meant Everything ashpublications.org/ashclini…

#ASH25 In patients with #myelofibrosis, the mutant CALR-specific monoclonal antibody INCA33989 was well tolerated as monotherapy or in combination with #ruxolitinib, with 37% and 30% of patients having SVR25 and SVR35, respectively, at 24 weeks: ow.ly/uk6G50XF6zu

Exciting stuff happening here at the @ASH_hematology Annual Meeting! #mpnsm @ClevelandClinic @CleClinicNews #ASH25

Imaging's Hidden Cost: There may be a link between #medical #imaging and childhood #BloodCancers. A retrospective cohort study found that 10.1% of #hematologic cancers in children may be caused by #radiation exposure from medical imaging.

Stop by our poster on Sunday! Paper No: 4340 Using a medically trained LLM-based end-to-end system in automating patient eligibility screening across a health system for A phase 3 study evaluating the safety of givinostat in patients with PV. #ASH25 @ClevelandClinic

Ahead of #ASH25, @AaronGerds, @n_gangat, and John O. Mascarenhas, MD, weigh in on the most anticipated presentations in #MPN.🩸 Sign up below to read their insights👇& ensure you're up to speed on the data poised to shape practice. 📊 @ASH_hematology 🔐onclive.com/view/all-eyes-ar…


Join us in #Cleveland for @OncLiveSOSS in hematologic malignancies! @ClevelandClinic. @OncLive

redcrossblood.app.link/blood… my last donation went to Philadelphia and Irvine! Coast-to-coast RBCs!


Positive Results from Prospective, Randomized, Phase 3 Registrational Trial of Pelabresib Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis consultqd.clevelandclinic.or… via @clevelandclinic @AaronGerds @CleClinicMD @ClevelandClinic

Socioeconomic disparities affect access to allogeneic hematopoietic stem cell transplantation for people with acute myeloid leukemia, according to data presented at #ASH24. Healio spoke with @AaronGerds of @caseccc about the findings. #AML #Leukemia healio.com/news/hematology-o…

Congrats to Dr. Natalie Wuliji of @fredhutch at #ASH24 for a wonderful plenary discussion! This study examined socioeconomic factors of patients undergoing #bmt for #AML. Honored to be a part of it. @ClevelandClinic @MukherzSudipto


#ASH24 Among patients with heavily pretreated, R/R #ChronicLymphocyticLeukemia, treatment with the #bispecific antibody #epcoritamab led to high rates of overall and complete response, as well as a high rate of uMRD: ow.ly/kZ4k50UmYFa

According to findings to be presented at #ASH24, reduced #DOAC dosing was found to be associated with a decreased #bleeding rate and lower #healthcare utilization in the setting of secondary prevention of #VTE: ow.ly/Nx6L50UmzMS